Acadia Pharmaceuticals (ACAD) Cash & Equivalents (2010 - 2026)

Acadia Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $282.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 29.64% year-over-year to $282.2 million; the TTM figure through Mar 2026 stood at $282.2 million (up 29.64% YoY), while the FY2025 annual figure was $177.7 million, down 44.4% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $282.2 million, up from $177.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $319.6 million in Q4 2024, with the low at $98.2 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $188.7 million (2023), against an average of $196.8 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 47.62% in 2022, then soared 69.4% in 2024.
• Acadia Pharmaceuticals' Cash & Equivalents stood at $114.8 million in 2022, then jumped by 64.27% to $188.7 million in 2023, then jumped by 69.4% to $319.6 million in 2024, then sank by 44.4% to $177.7 million in 2025, then soared by 58.82% to $282.2 million in 2026.
• Business Quant data shows ACAD's Cash & Equivalents at $282.2 million in Q1 2026, $177.7 million in Q4 2025, and $258.0 million in Q3 2025.